



Open Clinical Trials

September 2026

To refer a patient, please contact the disease specific nurse navigator directly to schedule a visit with one of our providers.

Please note that slot status may vary over time.

For more information regarding trials at the University of Colorado, please visit:

<https://researchstudies.cuanschutz.edu/>

Jump to Cancer Types

- [Breast](#)
- [Cutaneous](#)
- [Gastrointestinal](#)
- [Genitourinary](#)
- [Gynecologic](#)
- [Head and Neck](#)
- [Hematology](#)
- [Neuro-Oncology](#)
- [Phase 1, Expansion, Molecular Studies \(POEMs\)](#)
- [Radiation Oncology](#)
- [Sarcoma](#)
- [Thoracic \(Lung\)](#)
- [Cancer Prevention and Survivorship](#)

[Common Eligibility Criteria for Clinical Trials](#)

Location Key	
AMC	Anschutz Medical Campus, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045
CCMC	Cherry Creek Medical Center, 100 Cook St, Denver, CO 80206
HRH	Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO 80129
LT	Lone Tree Medical Center, 9548 Park Meadows Dr, Lone Tree, CO 80124

[Satellite Site Contacts](#)



Breast Cancer Medical Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Jane Jachowicz, BSN, RN	Jane.jachowicz@uchealth.org	Phone: 720-848-3537 Fax: 720-848-1774
Physician Leads	Email	Phone
Virginia Borges, MD	Virginia.borges@cuanschutz.edu	-
Peter Kabos, MD	Peter.kabos@cuanschutz.edu	-
Jennifer Diamond, MD	Jennifer.diamond@cuanschutz.edu	-

Metastatic Breast Cancer			
Study Name	Patients	NCT#	Sites
PRE-I-SPY Phase 1/1b Platform, PRE-Investigation of Serial Studies (24-1242)	Previously treated metastatic breast cancer	NCT05868226	AMC
Phase 3 trial of saruparib (PARP1i) plus camizestrant (SERD) vs MD choice of CDK4/6 plus endocrine therapy (24-1711)	ER+, HER2-, BRCA1, BRCA2 or PALB2 mutations	NCT06380751	AMC
Phase 3 Study of MK-2870 (Sac-TMT, ADC) +/- pembromizumab vs physician's choice therapy (24-1416)	HR+/HER2-negative metastatic breast cancer	NCT06312176	AMC CCMC HRH
Phase 3 CDK4/6i + fulvestrant +/- capivasertib (AKTi) (21-3077)	1L metastatic HR+HER2- breast cancer	NCT04862663	AMC, CCMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA mutation	NCT05768139	AMC (POEMs)
Phase 3 study of zanidatamab (HER2 bispecific ab) + standard therapy v. trastuzumab + standard therapy (24-1635)	Previously treated metastatic HER2+ breast cancer	NCT06435429	AMC, HRH, CCMC
Phase 1 study of BG-C9074 (B7H4 ADC Topoi) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer, no prior Topoi ADC	NCT06233942	AMC (POEMs)
Phase 1/2 study of MBRC-101 (EphA5 ADC MMAE) in select advanced solid tumors (23-2430)	Metastatic breast cancer	NCT06014658	AMC (POEMs)
CDK4/6 Inhibitor dosing knowledge (CDK) study (24-1798)	Metastatic breast cancer in older adults	NCT06377852	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
Phase II study of utidelone (UTD1) + capecitabine (25-0715)	HER2-negative Metastatic Breast Cancer Patients with Brain Metastases	NCT06764940	AMC
Phase Ib Study of bulumtaturg fuvodotin (Nectin-4 ADC MMAE) in previously treated metastatic TNBC (25-1309)	Previously treated metastatic TNBC, requires prior Topoi ADC and taxane	NCT06908928	AMC
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric, TNBC) with no other approved treatment options available	NCT07312903	AMC (POEMs)



A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer (24-1686)	HR+, HER2 – metastatic adenocarcinoma of breast not amenable to curative therapy. Progression with at least 2 prior lines of endocrine therapy, no prior chemotherapy	NCT06369285	AMC, HRH, CCMC
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 (KAT6A/KAT6B inhibitor) in Adult Participants with Advanced or Metastatic Solid Tumors (25-2398)	Advanced/metastatic ER+ HER2- breast cancer	NCT06784193	AMC
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant (Oral SERD and complete estrogen receptor antagonist) with Ribociclib (CDK4/6) Versus Letrozole (Aromatase inhibitor) with Ribociclib for the First-Line Treatment of ER+HER2 Advanced Breast Cancer (OPERA-02) (25-2524)	1L ER-positive, HER2-negative locally advanced or metastatic breast cancer	NCT07085767	AMC, LT, HRH, CCMC
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, (Nectin4/Trop2 ADC), as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors (26-0180)	Locally advanced or metastatic urothelial carcinoma and selected advanced/metastatic solid tumors – Urothelial Carcinoma, TNBC, SCCHN and Cervical Cancer	NCT07193511	AMC, LT (POEMs)
Early-Stage Breast Cancer			
ISPY2.2 neoadjuvant study (10-0374)	Stage II-III Breast cancer	NCT01042379	AMC, LT, HRH, CCMC
OFSET: Phase 3 study of chemotherapy v. ovarian suppression (23-2461)	Premenopausal HR+HER2- breast cancer	NCT05879926	AMC, LT, HRH, CCMC
OptimICE-PCR: De-escalation after pCR (23-1255)	TNBC with pCR to neoadjuvant therapy	NCT05812807	AMC, LT, HRH
S2206: Phase 3 trial of neoadjuvant durvalumab (PD-L1i) plus chemo vs chemo alone (24-0401)	MammaPrint ultrahigh ER/PR+, HER2-	NCT06058377	AMC, LT, HRH, CCMC
S2212 SCARLET: Shorter Anthracycline-Free Chemo Immunotherapy in Early TNBC (23-2438)	Early Stage TNBC	NCT05929768	AMC, CCMC LT HRH
A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade (25-2075)	Clinical Stage T1c-T3 N0-N1 (except T3N1) with pCR after neoadjuvant therapy (HER2+)	NCT06876714	AMC, CCMC LT HRH



Cutaneous Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Nurse navigator	melanoma@uchealth.org	Phone: 720-848-0505 Fax: 720-848-0614
Physician	Email	Phone
Sapna Patel, MD	Sapna.p.patel@cuanschutz.edu	720-848-0590

High-Risk Resected Melanoma No current trials available			
Advanced Melanoma			
Phase 2/3 study of LNS8801 (GPER agonist) +/- without pembrolizumab (25-0336)	Treatment refractory, unresectable melanoma	NCT06624644	AMC
TILVANCE-301: Phase 3 trial of Lifileucel (LN-144 tumor infiltrating lymphocyte) + pembro vs pembro alone (24-0982)	Untreated, unresectable or metastatic melanoma	NCT05727904	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L PD-L1+ melanoma 2L PD-L1+ melanoma	NCT05533697	AMC (POEMs)
IGNYTE-3: Phase 3 trial of vusolimogene oderparepvec (oncolytic virus) + nivolumab v. treatment of physician's choice (24-1672)	Advanced melanoma progressed on Anti-PD-1 and Anti-CTLA-4	NCT06264180	AMC
Phase 3 trial of fianlimab + cemiplimab vs relatlimab (LAG-3i) and nivolumab (24-1713)	Unresectable or metastatic melanoma	NCT06246916	AMC
SUPRAME: Phase 3 study of IMA203 (autologous T-cell receptor-engineered T cell therapy targeting PRAME) versus investigator's choice in patients with melanoma (25-0844)	Unresectable or previously treated cutaneous melanoma; HLA-A*02:01 positive, Disease progression (resistance or toxicity) on at least 1 PD-1 inhibitor	NCT06743126	AMC
A Phase 1b/2a study of Oral 7HP349 (Alintegimod, immunomodulator) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies (25-0578)	Locally Advanced or metastatic Melanoma	NCT06362369	AMC
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101) (25-2206)	Recurrent/progressing melanoma that has received or not eligible for all SOC. HLA-A*02:01 positive	NCT03686124	AMC
Lipid lowering therapy for atherosclerotic disease in melanoma patients receiving immune checkpoint inhibitors (25-1921)	Melanoma diagnosis without prior Immune Checkpoint Inhibitor use, going on Immune Checkpoint Inhibitor as SOC therapy	NCT07704918	AMC
A First-in-human Study of RLY-8161 (NRAS Inhibitor) for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors (26-0306)	Unresectable Stage III or IV melanoma that is refractory to standard/	NCT07584226	AMC

	intolerant or declined therapy		
Neoadjuvant or Resectable Melanoma/			
No current trials available			
Uveal Melanoma			
OptimUM-10: Phase 3 study of neoadjuvant darovasertib (PKCi) in patients with non-metastatic uveal melanoma (25-2370)	Non-metastatic uveal melanoma	NCT07015190	AMC
TARGET-Tebe: A Phase II Study of KIMMTRAK (bispecific T-cell engager) in HLA-A*0201 positive untreated metastatic uveal melanoma (25-2068)	Untreated metastatic uveal melanoma positive for HLA-A*0201	NCT06070012	AMC
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101) (25-2206)	Recurrent and/or refractory uveal melanoma	NCT03686124	AMC
REVEAL: Phase 2/3 Study of RP2 (oncolytic virus) + nivolumab v. ipilimumab + nivolumab (25-0004)	Immune checkpoint inhibitor-naïve metastatic uveal melanoma; no more than 2 lines of systemic therapy	NCT06581406	AMC
Merkel Cell Carcinoma, Squamous Cell Carcinoma			
Clinical trial of IFx-Hu2.0 (cancer vaccine) added to pembrolizumab in IO naïve merkel cell carcinoma (25-0580)	Advanced or metastatic merkel cell carcinoma	NCT06947928	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	NCT07080242	AMC (POEMs)
NRG14-HN014: Phase 3 trial of neoadjuvant IO with response adapted treatment v. SOC for resectable Stage III/IV cutaneous squamous cell carcinoma (CSCC) (25-1924)	Invasive CSCC or regional lymph node or in-transit metastasis of CSCC	NCT06568172	AMC (RT)
Advanced Cutaneous Malignancies in Transplant Recipients			
No current trials available			



Gastrointestinal Oncology Anschutz Medical Campus (AMC)		
Nurse Navigators	Email	Phone
Kristen Miller	Kristen.Miller3@uchealth.org	Phone: 720-848-2639
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physicians	Email	Phone
Lindsey Davis, MD	Sarah.Davis@cuanschutz.edu	-
Chris Lieu, MD	Christopher.Lieu@cuanschutz.edu	-
Wells Messersmith, MD	Wells.Messersmith@cuanschutz.edu	-

Gastric, Gastroesophageal, and Gastroesophageal Junction (GEJ) Cancers			
Phase 3 study of rilvegostomig (bispecific ab) + fluoropyrimidine + trastuzumab deruxtecan v. trastuzumab, chemotherapy + pembrolizumab (ARTEMIDE-Gastric01/25-0646) (25-0646)	1L HER2 gastric cancer	NCT06764875	AMC
Phase 1 study of SGN-CEACAM5C (CEACAM5 ADC Topoi) advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
Phase 1 study of TJ033721 (Givastomig, Claudin 18.2 x 4-1BB bispecific ab) in metastatic gastric, GE and esophageal adenocarcinoma (21-3254)	1L metastatic gastric, GE, and esophageal adeno ca positive for CLDN18.2	NCT04900818	AMC
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8ab) + toripalimab +/- other treatments (25-1556)	2L Gastric, GEJ and Esophageal Adenocarcinoma and 2L esophageal squamous cell carcinoma	NCT06657144	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric, TNBC, CRC) with no other approved treatment options available	NCT07312903	AMC (POEMs)
BL-M05D1-ST-101: A Phase 1 study of BL-M05D1 (Claudin 18.2 ADC Topoi) in advanced solid tumors (25-1878)	2L + Gastric, GEJ or Esophageal Adenocarcinoma, 2L+ biliary cancers	NCT07021066	AMC
EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II (25-2369)	MSS gastric or GEJ Adenocarcinoma (cyt+) or peritoneal carcinomatosis. Must have received min 3 months and max 6 months of 1L systemic treatment	NCT07001748	AMC



Early-Stage Colorectal Cancer (CRC)			
CIRCULATE-US: Colon adjuvant chemotherapy based on evaluation of residual disease (22-0916)	Stage IIIA/B MSS colon adenocarcinoma following curative resection	NCT05174169	AMC, LT, HRH, CCMC
Phase 2 Single-Arm Rectal Cancer brachytherapy for patients with low-lying residual adenocarcinoma after total neoadjuvant therapy to improve organ preservation rates (25-1202)	MMR-Proficient low-mid rectal adenocarcinoma cT1-4, N0-2, M0	NCT07292298	AMC (RT Group)
Metastatic Colorectal Cancer (CRC)			
Phase I trial of AWN003694 + cetuximab + encorafenib (25-0300)	Refractory BRAF V600E metastatic CRC	NCT06102902	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	NCT06445062	AMC, LT
OrigAMI-3: Phase 3 study of FOLFIRI + amivantamab v cetuximab/bevacizumab in metastatic CRC (24-2380)	2L metastatic CRC KRAS/NRAS and BRAF WT	NCT06750094	AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma/ 2 nd Line CRC	NCT03715933	AMC (POEMs)
INTRINSIC: Phase 1/1b umbrella study of targeted therapies in metastatic CRC (21-3774)	Previously treated advanced or metastatic CRC with PIK3CA mutation +/- RAS mutation	NCT04929223	AMC
CARAPIA-1: Phase 1 study of GCC19CART in metastatic CRC. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i> (22-0697)	Previously treated metastatic CRC, GCC+, MSS	NCT05319314	AMC
Phase 1 study of SGN-CEACAM5C (CEACAM5 ADC Topoi) advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
AE2222: PUMP: Phase 3 study of systemic therapy +/- hepatic arterial infusion for unresectable CRC liver mets (24-0029)	Unresectable liver metastatic CRC	NCT05863195	AMC
Phase 1 study of JNJ-89402638 (bispecific ab) for metastatic CRC (24-1600)	3L+ unresectable metastatic CRC	NCT06663319	AMC
Phase 1 study of BI1831169 (oncolytic virus) +/- ezabenlimab (anti-PD-1) in advanced solid GI tumors (23-2048)	Advanced or metastatic GI tumors with no standard therapies	NCT05155332	AMC
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC (POEMs)
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8) + toripalimab with or without other treatments in participants with advanced or metastatic solid tumors (25-1556)	4L + CRC	NCT06657144	AMC
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric, TNBC, CRC) with no other approved treatment options available	NCT07312903	AMC (POEMs)



DSP107_003: Phase 2b study of DSP107 (bi-specific 4-1BB T-cell engager) + atezolizumab v. fruquintinib in advanced microsatellite stable CRC (26-0039)	MSS or pMMR CRC progressed or intolerant to 5FU, oxaliplatin, irinotecan, anti-VEGF and anti-EGFR (if RAS WT). No more than 3 prior lines of therapy	NCT07235293	AMC, HRH
MRG007-001/ARR-217-101: Phase 1 study of MRG007 (ARR-217, CDH17 ADC) in advanced solid tumors (25-2495)	Advanced or metastatic solid tumor that has failed or intolerant to standard therapy. Phase 1b is CRC Only	NCT07066657	AMC
DSP107_003: A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 (CD47 x CD137) in Combination with Atezolizumab (PD-L1) Versus Fruquintinib (VEGFR TKI) in Patients with Advanced Microsatellite Stable Colorectal Cancer (26-0039)	Advanced or metastatic MSS/pMMR CRC that has failed or intolerant to standard therapy including 5FU, Irinotecan, Oxaliplatin, Lonsurf, Bev and mutational targeting therapies if applicable	NCT07235293	AMC, HRH
A Phase 1 First-in-human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 (pan-RAS) Monotherapy and in Combination in Patients with Advanced Solid Tumors (26-0780)	Locally Advanced or metastatic NSCLC, BTC, CRC or PDAC who have progressed on standard therapy. No prior RAS therapy allowed	NCT06983743	AMC (POEMs)
Protocol 10716, A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer (26-1297)	Advanced or metastatic MSS/pMMR CRC that has failed or intolerant to standard therapy	NCT07147231	AMC
Liver Cancer			
Phase Ib/2 study of multiple immunotherapy based treatment combinations (24-1787)	Locally advanced/metastatic /unresectable HCC; no priory treatment	NCT04524871	AMC, HRH, CCMC
Phase 1b/2 study of TTI-101 (STAT3i) in advanced or metastatic HCC (22-1621)	1-3L Unresectable, locally advanced or metastatic HCC	NCT05440708	AMC
Biliary Tract Cancer			
Protocol 10608, A phase II trial of durvalumab with gemcitabine and cisplatin as neoadjuvant therapy for high-risk resectable intrahepatic cholangiocarcinoma (24-0573)	Resectable intrahepatic cholangiocarcinoma	NCT06050252	AMC
D702NC00001: Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig (PD-1/TIGIT) or Durvalumab (PD-L1) in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) (26-0190)	Previously untreated advanced/ unresectable or metastatic biliary tract cancer	NCT07221253	AMC
Phase 1/2 study of patritumab deruxtecan (ADC) (24-1883)	2L + Biliary Tract Cancer	NCT06596694	AMC



A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (24-1250)	Cohort 3 – 2L Biliary Tract Cancer Cohort 4 – 1L Biliary Tract Cancer	NCT06428409	AMC, HRH, CCMC
A Phase 1 First-in-human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 (pan-RAS) Monotherapy and in Combination in Patients with Advanced Solid Tumors (26-0780)	Locally Advanced or metastatic NSCLC, BTC, CRC or PDAC who have progressed on standard therapy. No prior RAS therapy allowed	NCT06983743	AMC (POEMs)
Pancreatic Cancer			
Intraperitoneal paclitaxel for pancreatic ductal adenocarcinoma (24-2111)	Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis	NCT07030283	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	NCT06445062	AMC, LT
Phase 1/2 study of M3814 + hypofractionated radiation for locally advanced pancreatic adenocarcinoma (20-2093)	Locally advanced pancreatic adenocarcinoma following 4-6 months of neoadjuvant chemo	NCT04172532	AMC
Phase 1 study of SGN-CEACAM5C (CEACAM5 ADC Topoi) advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
Phase 1 study of CA-4948 (IRAK4/FLT3i) + gemcitabine+ nab-paclitaxel in metastatic pancreatic cancer (23-0613)	2-3L metastatic or unresectable pancreatic ductal adeno	NCT05685602	AMC
A Phase 1A/B Study to Evaluate the Safety and Tolerability Of EBC-129 (CEACAM5/6 ADC) As A Single Agent and In Combination with Pembrolizumab in Advanced Solid Tumors (23-0580)	Metastatic Pancreatic Adenocarcinoma	NCT05701527	AMC (POEMs)
MRG007-001/ARR-217-101: Phase 1 study of MRG007 (ARR-217, CDH17 ADC) in advanced solid tumors (25-2495)	Advanced or metastatic solid tumor that has failed or intolerant to standard therapy.	NCT07066657	AMC
223675: A Phase1b/2 study of GSK5764227 (B7-H3 ADC Topoi) alone and in combination in previously treated advanced unresectable or metastatic gastrointestinal solid tumors (25-1442)	2L Pancreatic adenocarcinoma (irinotecan naive)	NCT06885034	AMC
BL-M05D1-ST-101: A Phase 1 study of BL-M05D1 (Claudin 18.2 ADC Topoi) in advanced solid tumors (25-1878)	2L+ Pancreas Adenocarcinoma	NCT07021066	AMC
A Phase 1 First-in-human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 (pan-RAS) Monotherapy and in Combination in	Locally Advanced or metastatic NSCLC, BTC, CRC or PDAC who have progressed on standard	NCT06983743	AMC (POEMs)



Patients with Advanced Solid Tumors (26-0780)	therapy. No prior RAS therapy allowed		
Neuroendocrine Cancers			
COMPOSE: Study of peptide receptor radionuclide therapy with lutetium edotreotide v standard therapy for SSTR+ GI neuroendocrine tumors (21-3552)	Well-differentiated aggressive, grade 2/3, SSTR+ neuroendocrine tumors of gastroenteric or pancreatic origin	NCT04919226	AMC
NET Retreat: Phase 2 study of 177Lutetium retreatment v. everolimus in metastatic midgut neuroendocrine (23-1917)	Metastatic grade 1/2 midgut neuroendocrine tumors	NCT05773274	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	NCT07080242	AMC (POEMs)
CRN09682-191: A Phase 1/2 Dose Escalation Study of CRN09682 (NDC) With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors (25-2045)	Histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression	NCT07129252	AMC



Genitourinary Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Cyndie Harvey	Cynthia.Harvey@uchealth.org	Phone: 720-848-0170 Fax: 720-848-0180
Physician	Email	Phone
Laura Graham, MD	Laura.graham@cuanschutz.edu	-
Elizabeth Kessler, MD	Elizabeth.kessler@cuanschutz.edu	-

Localized Prostate Cancer			
Study Name	Patients	NCT#	Sites
S2210: Neoadjuvant carboplatin for patients with localized prostate cancer and germline BRCA1/2 mutations (23-2420)	Localized prostate cancer with germline BRCA1/2 mutation	NCT05806515	AMC
Pragmatic study of metformin v. lifestyle mods (19-1536)	Localized prostate cancer	NCT05515978	AMC
The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer (25-1121)	High Risk Prostate Adenocarcinoma	NCT05946213	AMC, HRH (RT)
Metastatic Prostate Cancer			
S1802: SST +/- surgery or radiation (18-2252)	Metastatic hormone sensitive prostate cancer	NCT03678025	AMC
KEYNOTE-365: Study of pembrolizumab combinations COHORT I: Carbo/Etop +/- pembro (21-3724)	De novo and treatment emergent neuroendocrine/small cell prostate cancer	NCT02861573	AMC
MK-5684-003: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0350)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent and taxane	NCT06136624	AMC, HRH, LT
MK-5684-004: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0742)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent	NCT06136650	AMC, HRH, LT
JNJ-87189401 and JNJ-78278343 (23-1990)	Metastatic castration-resistant prostate cancer	NCT06095089	AMC
Phase 1b/2a study of pocenbrodib alone or in combination with abiraterone acetate, olaparib, or 177Lu-PSMA-617 (24-2278)	Metastatic castration-resistant Prostate Cancer	NCT06785636	AMC
CCTG-PR26 - Randomized phase 3 clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors (TRIPLE-SWITCH) (25-0680)	Metastatic castration-sensitive prostate cancer and suboptimal PSA response	NCT06592924	AMC CCMC LT HRH
Phase 3 study of pasritamig (JNJ-78278343), a T-cell-redirecting agent targeting human kallikrein 2 v best supportive care for metastatic castration-resistant prostate cancer (25-1528)	Metastatic castration-resistant Prostate Cancer	NCT07164443	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of	NCT07080242	AMC (POEMs)



	DLL3 expression who have failed at least 1 line of standard therapy		
Alliance A032304 Radioligand Efficacy comparison by initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL) (26-0904)	Metastatic castration-resistant Prostate Cancer that has received at least one androgen receptor	NCT07200830	AMC
Bladder Cancer			
Phase 2 study of intravesicular instillation of TARA-002 (24-1264)	High grade non-muscle invasive bladder cancer	NCT05085990	AMC
EA8192 Preoperative durvalumab and/or chemo (21-3855)	Upper tract urothelial cancer	NCT04628767	AMC
MODERN: A032103 risk adapted adjuvant therapy - ctDNA testing and nivo+/- relatlimab or surveillance (24-0700)	Muscle invasive bladder cancer or upper tract urothelial cancer after surgery	NCT05987241	AMC
S1937: Eribulin + gemcitabine v. standard therapy (22-0927)	3L+ metastatic bladder cancer post PD1i	NCT04579224	AMC
NRG-GU015: Phase 3 trial of adaptive RT + chemo for muscle invasive bladder cancer (ARCHER) (25-2502)	CT2-T3,N0M0 Urothelial carcinoma of bladder	NCT07097142	AMC (RT)
S2427: Phase 2 study of bladder preservation with immunoradiotherapy after clinically meaningful response to neoadj therapy in muscle invasive bladder cancer (BRIGHT) (25-2505)	CT2-T4aN0M0 muscle invasive urothelial carcinoma of bladder	NCT07061964	AMC (RT)
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, (Nectin4/Trop2 ADC), as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors (26-0180)	Locally advanced or metastatic urothelial carcinoma and selected advanced/metastatic solid tumors – Urothelial Carcinoma, TNBC, SCCHN and Cervical Cancer	NCT07193511	AMC, LT (POEMs)
Kidney Cancer			
SAMURAI: Phase 2 study of SABR in patients receiving immunotherapy (24-2480)	Metastatic unresectable RCC	NCT05327686	AMC LT HRH CCMC
NEOPAX: Pembrolizumab + axitinib for RCC with IVC tumor thrombus (22-1669)	Neoadjuvant therapy for RCC with tumor thrombus	NCT05969496	AMC
HC-7366 + belzutifan for locally advanced or metastatic clear cell RCC (24-0745)	2L+ metastatic clear cell RCC	NCT06234605	AMC
STRIKE/A032201: Study of short term intensified pembrolizumab + tivozanib for high-risk renal cell carcinoma (25-0682)	Clear cell RCC following complete resection	NCT06661720	AMC HRH CCMC LT
A092204: Phase 2 study of cabozantinib + cemiplimab v cabozantinib in	Locally advanced unresectable or	NCT06900595	AMC



adolescents and adults with advanced adrenocortical cancer (25-2801)	recurrent/metastatic adrenocortical carcinoma		
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (25-1976)	2L Unresectable locally advanced or metastatic renal cell carcinoma with a primary clear cell component that has recieved anti-PD-1 oranti-PD-L1 as part of most recent regimen	NCT07011719	AMC, HRH, LT
Penile Cancer			
EA8134 InPACT: Neoadjuvant chemo + ILND v chemo +RT+ILND v ILND (17-1515)	Penile cancer	NCT02305654	AMC



Gynecologic Oncology Anschutz Medical Campus (AMC)			
Nurse Navigator	Email	Phone	
Clinic schedulers	-	Phone: 303-724-2066	
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474	
Physician	Email	Phone	
Brad Corr, MD	Bradley.corr@cuanschutz.edu	-	
Ovarian Cancer - Frontline			
Study	Patients	NCT#	Sites
GOG-3068 HOTT HIPEC: Phase 3 study of HIPEC + cisplatin v no HIPEC at time of cytoreductive surgery followed by niraparib in stage III and IV ovarian cancer (23-2189)	Newly diagnosed stage III/IV ovarian, primary peritoneal, and fallopian tube cancer treated with neoadj chemo	NCT05659381	AMC
Ovarian Cancer - Maintenance			
UPROAR: Phase 2 study of maintenance mirvetuximab soravtansine (ADC) and olaparib in recurrent platinum sensitive, ovarian cancer (22-0384)	Recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancer	NCT05887609	AMC
NRG-GY036: Phase 3 trial of one vs. two years maintenance olaparib, +/- bevacizumab (25-0399)	BRCA1/2 mutated or HRD+ ovarian cancer following response to 1L platinum-based chemotherapy	NCT06580314	AMC CCMC HRH
Ovarian Cancer - Recurrent			
VOLAstra: Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer (23-1991)	CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	NCT05902988	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	NCT06233942	AMC (POEMs)
A Phase 1b study of psilocybin assisted psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission (23-1455)	Clinical stage 1 or 2, completed primary treatment, risk of recurrence at 10 years <20%	NCT06430541	AMC
Phase I study of CLK/DYRK (Cirtuvivint) + olaparib in BRCA/HRD platinum resistant ovarian cancer (24-1749)	Platinum-resistant ovarian cancer with 1-3 prior lines of therapy. BRCA or HRD + with prior parp inhibitor.	NCT06856499	AMC
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic refractory Ovarian Adenocarcinoma	NCT06014658	AMC (POEMs)
CORT125134-557: An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant (GR antagonist/modulator) in Combination	Platinum-resistant and platinum-sensitive epithelial ovarian, peritoneal or fallopian-tube carcinoma	NCT06906341	AMC



with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA) (26-0057)			
A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients with Locally Advanced or Metastatic Solid Tumors, including High-Grade Serous Ovarian Cancer (26-0522)	Histologically confirmed solid tumors who have locally recurrent or metastatic disease, prioritizing HGSOc	NCT06799065	AMC (POEMs)
Ovarian Cancer – Low Grade			
No current studies available			
Endometrial Cancer - Presurgical			
No current studies available			
Endometrial Cancer - Frontline			
NRG GY026: Phase 2/3 study of paclitaxel/carboplatin +/- hylecta or phesgo in HER2+ endometrial cancer (22-1764)	1L Stage I-IV endometrial serous carcinoma, carcinosarcoma, or other histology HER2+	NCT05256225	AMC, HRH, CCMC
NRG GY032: Phase 2 study of tailored adjuvant therapy in POLE-mutated p53 WT early-stage endometrial cancer (24-1417)	1L Stage I-III endometrial cancer POLE-mutated, p53 WT, completed surgery	NCT06388018	AMC
Endometrial Cancer - Recurrent			
GOG-3082: Phase 1b/2 basket study of ACR-368 (CHK1/2i) +/- gemcitabine in platinum-resistant ovarian, endometrial and urothelial ca based on acrivon oncosignature (23-0115)	Up to 2L in recurrent setting: Recurrent, platinum-resistant ovarian cancer, endometrial adenoca, urothelial carcinoma with Acrivon Oncosignature Status	NCT05548296	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	NCT06233942	AMC (POEMs)
223559 (BEHOLD-2): A Phase 1/2 Randomized Multi-Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan (ADC) in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors (25-0945)	Advanced or recurrent Endometrial Cancer	NCT06796907	AMC
224035 (NERT): A Phase 1/2 open-label, multicenter study of oral GSK5460025 (NER) alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors (25-2741)	Advanced Endometrial Cancer that has received at least 1 but no more than 3 lines of systemic therapy	NCT07213609	AMC
Cervical Cancer			
NRG-GY037: A Phase III Study of Induction Pembrolizumab and	High Risk Locally Advanced Cervical Cancer	NCT07061977	AMC, HRH



Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer (25-2515)			
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, (Nectin4/Trop2 ADC), as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors (26-0180)	Locally advanced or metastatic urothelial carcinoma and selected advanced/metastatic solid tumors – Urothelial Carcinoma, TNBC, SCCHN and Cervical Cancer	NCT07193511	AMC, LT (POEMs)
Uterine Leiomyosarcoma			
GOG 3088: Phase 2 study of letrozole v. observation in uterine leiomyosarcoma (24-0041)	Newly diagnosed ER+ uterine leiomyosarcoma	NCT05649956	AMC, HRH
BRCA Mutation Carriers			
SOROC: Study of salpingectomy v. salpingo-oophorectomy to reduce risk of ovarian cancer in BRCA1 carriers (20-2079)	BRCA1 germline mutation carriers with no prior cancer diagnosis age 35-50	NCT04251052	AMC, HRH



Head and Neck Cancer Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Kristen Miller	Kristen.Miller3@uchealth.org	Phone: 720-848-2639
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physician	Email	Phone
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	-

Head and Neck Cancer			
Study Name	Patients	NCT#	Sites
FORTIFI-HN010: Phase 2/3 study of ficerafusp alfa (BCA101) v. placebo + pembrolizumab (25-0122)	1L PD-L1-positive, recurrent or metastatic HNSCC	NCT06788990	AMC
eVOLVE-HNSCC: Phase 3 study of volrustomig v. observation in unresected locally advanced HNSCC (23-2332)	Unresected locally advanced HNSCC who have not progressed following definitive concurrent chemoRT	NCT06129864	AMC, HRH
OrigAMI-4: Phase 1b/2 study of amivantamab monotherapy + standard therapy in recurrent/metastatic HNSCC (24-0472)	Locally Advanced treatment naïve and eligible for surgery HNSCC	NCT06385080	AMC
Phase 1b study of losartan, pembrolizumab and SBRT in locoregionally recurrent refractory or oligometastatic HNSCC (24-1630)	locoregionally recurrent refractory or oligometastatic HNSCC	NCT06211335	AMC, HRH
NRG- HN010: Phase 2 study of docetaxel + trastuzumab v. T-DM1 for HER2+ salivary gland cancer (22-2363)	Recurrent, metastatic, or treatment-naïve, unresectable HER2+ salivary gland cancer	NCT05408845	AMC, HRH
A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma (25-1457)	Pheochromocytoma or paraganglioma that is unresectable and failed or declined SOC	NCT07282587	AMC
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, (Nectin4/Trop2 ADC), as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors (26-0180)	Locally advanced or metastatic urothelial carcinoma and selected advanced/metastatic solid tumors – Urothelial Carcinoma, TNBC, SCCHN and Cervical Cancer	NCT07193511	AMC, LT (POEMs)



Hematology Clinical Trials Unit Anschutz Medical Campus (AMC)		
Nurse Navigator UCH-BDC Intake Team	Email UCH-BDCIntakeTeam20181018184924@uchealth.org	Phone 720-848-2595
Doc Line Phone: 720-848-2628 (doc line)		
Physician	Email	Phone
Leukemia: Dan Pollyea, MD	Daniel.pollyea@cuanschutz.edu	720-848-8084
Cell Therapy/Stem Cell Transplant: Jon Gutman, MD	Jonathan.gutman@cuanschutz.edu	720-848-0220
Lymphoma: Manali Kamdar, MD	Manali.kamdar@cuanschutz.edu	720-848-0752
Multiple Myeloma: Dan Sherbenou, MD, PhD	Daniel.sherbenou@cuanschutz.edu	303-724-9520
Benign Heme and MPNs: Brandon McMahon, MD	Brandon.mcmahon@cuanschutz.edu	720-848-8868

Leukemia			
Study	Patients	NCT#	Sites
Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T cells in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML)	Relapsed/refractory disease. ≥5% blasts in the bone marrow or peripheral blood by morphology, flow cytometry, or immunohistochemistry after a minimum of 1 cycle of a hypomethylating agent (HMA) and venetoclax (Ven) combination (Ven/HMA)	NCT07347418	AMC
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (PI: C. McMahon/ 25-0091)	Relapsed and/or refractory CD33 positive AML that has failed initial standard therapy	NCT06714591	AMC
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (PI: C. McMahon/25-1278)	<u>Nonintensive Therapy Study (Ven+Aza)</u> • NPM1-m, >75 years of age, Age <75 and unfit for IC based on comorbidities <u>Intensive Therapy Study (7+3)</u> • NPM1-m or KMT2A-r, Age >18, FLT3 wild-type or ITD ratio <0.05 OR ineligible to receive FLT3-targeted therapy (medically ineligible or mutation in which FLT3 inhibition is not SOC). Lack of access to an FLT3 inhibitor is not considered “ineligible” for FLT3-targeted therapy, Fit for IC per Investigator opinion	NCT07007312	AMC
Phase 1b study to evaluate eganelisib as monotherapy and in combination	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	NCT06533761	AMC

with cytarabine in patients with relapsed/refractory acute myeloid leukemia (PI: McMahon, C/24-2332)			
Phase I study of SNDX-5613 in patients with relapsed/refractory leukemias including those harboring an MLL/KMT2A gene rearrangement or nucleophosmin1 (NPM1) Mutation (PI: McMahon C/ 22-1050)	Relapsed/refractory AML; ECOG of ≤ 2 ; adequate organ function	NCT04065399	AMC
Phase I study of CD19 directed CAR T Cells in adult patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with minimal residual disease (MRD) positivity at first complete remission (PI: Schwartz/22-0054)	Ages ≥ 18 ; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤ 2	NCT05535855	AMC
Study of Mitoxantrone for venetoclax-resistant AML (PI: Kent/24-0178)	Non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)	NCT06429449	AMC
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogeneic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	NCT05473910	AMC
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab vs. venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy (PI: McMahon/24-0685)	Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts). Previously untreated AML. Deemed unfit for intensive therapy.	NCT06384261	AMC
Study of cladribine + venetoclax after failure of venetoclax + hypomethylating agent in monocytic AML (PI: McMahon/23-0273)	Ages ≥ 18 ; Relapsed/Refractory AML; ECOG of ≤ 2	NCT06232655	AMC
KO-MEN-007: Phase 1 study of venetoclax/azacitidine or venetoclax + ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) + ziftomenib for AML (PI: McMahon/23-0061)	Ages ≥ 18 ; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of ≤ 2	NCT05735184	AMC
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms (PI: Anglos/25-0787)	Diagnosis of either ET or MF as defined by the 2022 WHO criteria. Adequate organ function	NCT06150157	AMC



Phase I/2 Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-D22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL) (PI: Angelos/ 22-1502)	Patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)	NCT04150497	AMC
Myelodysplastic Syndrome Trials			
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogeneic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	NCT05473910	AMC
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)	DIPSS score of 3 to 4 (intermediate 2 risk) or ≥ 5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria	NCT05320198	AMC
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)	Subject must have confirmation of high risk CCUS (defined by CHR5 score) or the diagnosis of MDS in the lower risk category as defined by IPSS-M less than 0; adequate organ function	NCT07579429	AMC
Lymphoma			
A Phase 3, randomized controlled trial of Rondecabtagene autoleucel, an autologous, dual-targeting CD 19/CD20 CAR-T cell product candidate, vs. Investigator's choice of CD19 CAR-T cell therapy in patients with relapsed or refractory large b-cell lymphoma in the second-line setting (PINACLE-H2H)	relapsed or refractory large b-cell lymphoma in the second-line setting; adequate organ function	NCT07188558	AMC
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma	Histologically confirmed primary central nervous system (CNS) lymphoma (PCNSL) prior to screening, as assessed by local pathology; transplant ineligible	NCT07015242	AMC
Phase I study of patient-derived multi-tumor associated antigen specific T-cells (MT-601) in patients with	Diagnosis of NHL, HL or CLL; ECOG or zero or 1; adequate organ function	NCT05798897	AMC

relapsed/refractory non- hodgkin lymphoma (PI: Kamdar/23-0056)			
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (PI: Milgrom/24-2065)	Newly diagnosed Stage I and II classic Hodgkins Lymphoma	NCT05675410	AMC (RT Group)
S2308: Randomized Phase 3 study of mosunetuzumab vs. rituximab for low tumor burden follicular lymphoma (PI: Kamdar/ 25-0024)	Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.	NCT06337318	AMC
A Phase 1a/1b trial in relapsed/refractory T-cell non-hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for intravenous infusion (PI: Haverkos/24-0458)	Ages > 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL	NCT04234048	AMC
Phase Ib Study of mosunetuzumab or glofitamab + CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma (PI: Kamdar/22-0939)	Ages ≥ 18; ECOG of ≤2	NCT05169515	AMC
Phase 1/1b study of bispecific CD19 and CD22 chimeric antigen receptorCo-expressing T cells (CD19x22 CAR T) in adolescent and adult patients with relapsed and/or refractory B-NHL (PI: Kamdar/21-2578)	Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1	NCT05098613	AMC
Phase 3 Study comparing the combination of beleodaq-CHOP or folotyn-COP to the CHOP regimen alone (24-2331)	Newly Diagnosed Patients with Peripheral T-Cell Lymphoma	NCT06072131	AMC
Multiple Myeloma			
A Phase 1, study of CB-011, a CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (CaMMouflage Trial) (PI: Sherbenou/23-0376)	Ages ≥ 18; Diagnosed MM and evidence of PD based on IMWG criteria; ECOG of ≤1	NCT05722418	AMC
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4 (PI: Monge/24-2397)	Newly diagnosed MM; post Auto stem cell transplant	NCT05243797	AMC
A phase 1b/2, open-label study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory	Ages ≥ 18; Received at least three prior MM treatment lines of therapy; Have received as part of	NCT05850234	AMC



multiple myeloma remission (PI: Monge Urrea/24-2523)	their previous therapy a PI and IMiD and an antiCD38 antibody		
Benign Heme			
Phase 3 study of bomedemstat (MK-3543/IMG-7289) v. best available therapy (24-2052)	Essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea	NCT06079879	AMC
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)	DIPSS score of 3 to 4 (intermediate 2 risk) or ≥ 5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria	NCT05320198	AMC
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms (PI: Mat Angelos/25-0787)	Positive for a calreticulin (CALR) driver mutation of essential thrombocythemia (ET) or myelofibrosis (MF)	NCT06150157	AMC
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (PI: Duarte/25-1016)	Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review	NCT04910685	AMC
Allo Transplant/GVHD			
No active trials			



Neuro-Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Clinic scheduler	-	Phone: 720-848-0300
Ana Lara-Rocha	Ana.Lararocha@uchealth.org	Phone: 720-848-9264
Physician	Email	Phone
Denise Damek, MD	Denise.damek@cuanschutz.edu	-

Neuro-Oncology			
Study	Patients	NCT#	Sites
Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)	Recurrent GMB	NCT05739942	AMC (CReST)
GBM AGILE: Phase 2/3 platform trial evaluating multiple regimens for glioblastoma (19-0744)	Newly diagnosed GBM	NCT03970447	AMC
A071401 Phase 2 study of SMO/AKT/NF2 inhibitors in progressive meningiomas (15-1747)	Progressive meningiomas with AKT1, PIK3CA or PTEN mutations	NCT02523014	AMC
Protocol 10505, A phase 1 and randomized phase 2 trial of selinexor and temozolomide in recurrent glioblastoma (23-0099)	Glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or bx upon 1 st recurrence. Has received 1L treatment of temozolomide + rt	NCT05432804	AMC
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1)-mutant glioma (25-1162)	newly diagnosed astrocytoma (Grade 2-4) following standard temozolomide therapy, as well as select patients with Grade 3 oligodendroglioma who have experienced progression/recurrence after surgical resection.	NCT05303519	AMC



Phase 1, Expansion, Molecular Studies (POEMs) Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Contact Disease Site Specific Nurse Navigator (ie Breast Cancer, GI, GU, etc.)		
Physician	Email	Phone
Jennifer Diamond, MD	jennifer.diamond@cuanschutz.edu	-
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	-

POEMs Studies			
Study	Patients	NCT#	Sites
Phase I study of RO7673396 (pan-RASi) as single agent and in combination with other anticancer therapy (25-0860)	Advanced solid tumors with RAS mutations	NCT06884618	AMC (POEMs)
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations Priority NSCLC	NCT06561685	AMC (POEMs)
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma/ 2 nd Line CRC	NCT03715933	AMC (POEMs)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L melanoma 2L melanoma	NCT05533697	AMC (POEMs)
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA kinase and helical mutations	NCT05768139	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic breast cancer, NSCLC (adeno and Sq Cell)	NCT06014658	AMC (POEMs)
Phase 1 study of BG-C9074 (B7H4 ADC Topoi) +/- tislelizumab (24-1128)	Metastatic breast, endometrial and platinum resistant ovarian, no prior Topoi ADC	NCT06233942	AMC (POEMs)
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors (24-0554)	KRASG12C mutated NSCLC	NCT06128551	AMC (POEMs)
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway (CRC, Gastric, NSCLC, TNBC) activated with no other approved treatment options available	NCT07312903	AMC (POEMs)
Phase I study of BG-C477 (CEACAM5 ADC Topoi) in Patients with Selected Advanced Solid Tumors (25-2371)	Phase 1A NSCLC treated with at least 2 prior lines Phase 1B 1L NSCLC with CEA high expression positive PD-L1 expression	NCT06596473	AMC (POEMs)



Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	NCT07080242	AMC (POEMs)
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, (Nectin4/Trop2 ADC), as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors (26-0180)	Locally advanced or metastatic urothelial carcinoma and selected advanced/metastatic solid tumors – Urothelial Carcinoma, TNBC, SCCHN and Cervical Cancer	NCT07193511	AMC, LT (POEMs)
A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients with Locally Advanced or Metastatic Solid Tumors, including High-Grade Serous Ovarian Cancer (26-0522)	Histologically confirmed solid tumors who have locally recurrent or metastatic disease, prioritizing HGSOc	NCT06799065	AMC (POEMs)
A Phase 1 First-in-human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 (pan-RAS) Monotherapy and in Combination in Patients with Advanced Solid Tumors (26-0780)	Locally Advanced or metastatic NSCLC, BTC, CRC or PDAC who have progressed on standard therapy. No prior RAS therapy allowed	NCT06983743	AMC (POEMs)



Radiation Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Pam Miranda	Pamela.miranda@uchealth.org	Phone: 720-848-0224 Fax: 720-848-0113
Physician	Email	Phone
Christine Fisher, MD	Christine.fisher@cuanschutz.edu	-
Rachel Rabinovitch, MD	Rachel.Rabinovitch@cuanschutz.edu	-

Radiation Oncology-Breast Cancer			
No currently active studies			
Radiation Oncology-Colorectal Cancer			
Study	Patients	NCT#	Sites
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients with Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates (25-1202)	Residual Adenocarcinoma after total neoadjuvant therapy	NCT07292298	AMC (RT)
Radiation Oncology- Genitourinary Cancer			
NRG-GU015: Phase 3 trial of adaptive RT + chemo for muscle invasive bladder cancer (ARCHER) (25-2502)	CT2-T3,N0M0 Urothelial carcinoma of bladder	NCT07097142	AMC (RT)
S2427: Phase 2 study of bladder preservation with immunoradiotherapy after clinically meaningful response to neoadj therapy in muscle invasive bladder cancer (BRIGHT) (25-2505)	CT2-T4aN0M0 muscle invasive urothelial carcinoma of bladder	NCT07061964	AMC (RT)
The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer (25-1121)	High Risk Prostate Adenocarcinoma	NCT05946213	AMC, HRH (RT)
Radiation Oncology - Lymphoma			
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (24-2065)	Newly diagnosed Stage I and II classic hodgkins lymphoma	NCT05675410	AMC
Radiation Oncology -Lung Cancer			
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	NCT05624996	AMC, LT, HRH
DURABLE: Delayed or upfront brain Radiotherapy (24-1615)	naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and ALK rearrangement	NCT05987644	AMC
Radiation Oncology-Pancreatic Cancer			
No currently active studies			
Radiation Oncology –Neuro Oncology			
No currently active studies			
Radiation Oncology-Multiple Cancer Types			
No current trials available			



Sarcoma Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Erica Becker, PA-C	Erica.becker@cuanschutz.edu	Phone: 720-848-9395 Fax: 720-848-5245
Sarah Reynolds, ONN-CG, RN	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201 Fax: 720-848-0160
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physician	Email	Phone
Breelyn Wilky, MD	Breelyn.wilky@cuanschutz.edu	-

Sarcoma			
Study	Patients	NCT#	Sites
Phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (25-0217)	Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas	NCT05711615	AMC
STRASS 2 (EA7211): Phase 3 study of neoadjuvant chemo followed by surgery v surgery alone high-risk retroperitoneal sarcoma (23-1625)	High risk retroperitoneal sarcoma (LPS/LMS)	NCT04031677	AMC
EA7222: Phase 3 trial of doxorubicin +/- pembrolizumab undifferentiated pleomorphic sarcoma (24-2043)	Undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas	NCT06422806	AMC
Phase 3 double blind randomized placebo-controlled study of ivosidenib in pts over 18 yo with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (24-1378)	Locally advanced or metastatic conventional chondrosarcoma with IDH1 mutation	NCT06127407	AMC
A Phase I/Ib Study of losartan in combination with sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (18-2740)	Osteosarcoma	NCT03900793	CHCO, AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	NCT03715933	AMC (POEMs)
A phase II study on efficacy and tolerability of weekly doxorubicin in elderly patients (24-0118)	Advanced or Metastatic Leiomyosarcoma of Soft Tissue	NCT07125183	AMC
Phase 1/2, open-label, dose escalation and expansion study of ADCE-D01, a humanized anti-human uPARAP antibody linked to a topoisomerase I inhibitor (24-2281)	Metastatic and/or Unresectable Soft Tissue Sarcoma	NCT06797999	AMC
Multi-cohort, open-label, Phase 1/2 study of DCC-3009 in participants with gastrointestinal stromal tumors (GIST) (24-2282)	GIST	NCT06630234	AMC
Phase 3 study of lurbinectedin + doxorubicin v. doxorubicin (SaLuDo) (25-0027)	1L metastatic leiomyosarcoma	NCT06088290	AMC



Phase 1 study of ziftomenib + imatinib (25-0466)	GIST after imatinib failure	NCT06655246	AMC
A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors (25-2227)	Part 1a: solid tumor with documented WPAM, at least 1 prior line of systemic therapy, progressed or was nonresponsive, or is unfit for available therapies. Evaluable or measurable disease per RECIST. Part 1d: Confirmed desmoid tumor, ≥10% in the active component of the tumor per investigator assessment within 12 months prior to the first dose. Treatment naïve or recurrent/refractory disease following at least 1 line of therapy	NCT05919264	AMC
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) (TKI) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3) (25-2548)	Histologically or cytologically confirmed GIST that is metastatic or unresectable with disease progression or intolerance to imatinib	NCT07218926	AMC



Thoracic (Lung) Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Courtney Sorensen, RN	Courtney.thoutt@uchealth.org	Phone: 720-848-2962 Fax: 720-848-0360
Physician	Email	Phone
Tejas Patil, MD	Tejas.patil@cuanschutz.edu	-
Erin Schenk, MD, PhD	Erin.schenk@cuanschutz.edu	-

Early-Stage NSCLC			
Study	Patients	NCT#	Sites
NAUTIKA-1: Phase 2 study of neoadjuvant and adjuvant biomarker-selected therapy for NSCLC (22-1484)	Stage IB-III NSCLC ALK fusion, (Neoadjuvant TKIs x 8 w), PD-L1+ > 1% (atezo + SBRT) (Only ALK Fusion Cohort open)	NCT04302025	AMC
V940-009: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (24-2314)	Neo-adjuvant (Stage II-IIIB(N2)) NSCLC	NCT06623422	AMC
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	NCT05624996	AMC, LT, HRH (RT Group)
1 st Line Metastatic NSCLC			
Phase 3 study of vonescimab v. pembrolizumab (25-0500)	First line Metastatic NSCLC with High PD-L1 expression	NCT06767514	AMC
Study of response of bony metastasis for patients on TKI or systemic treatment (19-0392)	NSCLC with completed molecular testing; receiving standard of care TKI or systemic therapy for actionable driver	NCT03958565	AMC, LT
M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Pembrolizumab in Advanced or Metastatic Non- Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) (25-0149)	Advanced/Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations	NCT06772623	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50%	NCT05533697	AMC (POEMS)
Phase I study of BG-C477 (CEACAM5 ADC Topoi) in Patients with Selected Advanced Solid Tumors (25-2371)	Phase 1B 1L NSCLC with CEA high expression and positive PD-L1 expression	NCT06596473	AMC (POEMS)



A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer (25-1395)	1 L NSCLC	NCT06892548	AMC
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib (EGFR TKI) Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA) (26-0358)	First-line EGFR PACC-mutated locally advanced or metastatic NSCLC	NCT07185997	AMC
EGFR mutant NSCLC			
LungMAP S1900G: Phase 2 study of osimertinib + capmatinib +/- ramucirumab (23-0936)	Metastatic NSCLC EGFR mutant with MET amplification as resistance	NCT05642572	AMC
Systimmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoisomerase payload) in metastatic NSCLC (23-2288)	Metastatic NSCLC with EGFR mutation	NCT05983432	AMC
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (25-1494)	Metastatic non-squamous NSCLC with classical EGFR mutation (Exon 19 Del or Exon 21 L858R). No prior EGFR TKI in locally advanced/metastatic setting	NCT07005102	AMC
ALK, ROS1, or RET rearranged NSCLC			
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC (25-2822)	ALK positive NSCLC	NCT07491497	AMC
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 (ROS-1) in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) (21-4641)	Any ROS1 + solid tumor other than NSCLC. For Adolescents older than 12 yo any ROS1 + solid tumor including NSCLC	NCT05118789	AMC
Expanded Access Treatment of Neladalkib (NVL-655) (ALK TKI) in Patients with Advanced ALK+ NSCLC or Other ALK+ Solid Tumors (25-0795)	ALK- Positive locally advanced or metastatic NSCLC who has received at least one prior ALK TKI	NCT06834074	AMC
MET or HER2 altered NSCLC			



SWOG S1900K: Phase 2 study of tepotinib +/- ramucirumab for MET exon 14 skip NSCLC (24-0486)	MET exon skip metastatic NSCLC	NCT06031688	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC	NCT05983432	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced cancers harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
KRAS or BRAF altered NSCLC			
Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors (24-0554)	KRASG12C mutated NSCLC	NCT06128551	AMC (POEMs)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (25-1233)	Advanced NSCLC with KRAS G12C	NCT06343402	AMC
A Phase 1 First-in-human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 (pan-RAS) Monotherapy and in Combination in Patients with Advanced Solid Tumors (26-0780)	Locally Advanced or metastatic NSCLC, BTC, CRC or PDAC who have progressed on standard therapy. No prior RAS therapy allowed. Must have KRAS G12X or G13X	NCT06983743	AMC (POEMs)
2nd Line and Beyond Metastatic NSCLC: ADCs, cytotoxics, radiation			
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic NSCLC (adeno and SCC)	NCT06014658	AMC (POEMs)
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (25-2371)	Phase 1A NSCLC with CEA high Expression treated with at least 2 prior lines	NCT06596473	AMC (POEMs)
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer (25-1395)	2 L NSCLC	NCT06892548	AMC
2nd Line and Beyond Metastatic NSCLC: Immunotherapy agents and Small Molecules			
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations	NCT06561685	AMC (POEMs)
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway	Solid Tumors known to be Wnt-Pathway activated (NSCLC) with no other approved treatment options available	NCT07312903	AMC (POEMs)



Activated Solid Tumors Where No Other Treatments Exist (25-2381)			
Small Cell Lung Cancer			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung (20-0359)	Small-Cell Lung Cancer	NCT04155034	AMC, HRH
MK-6070-002: A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (25-0794)	Relapsed/Refractory Extensive-Stage SCLC	NCT06780137	AMC
PRISM: PREcision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (25-2349)	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	NCT06769126	AMC, North, South
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC and SCLC	NCT05983432	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	NCT07080242	AMC (POEMs)
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer (25-1395)	1L and 2L+ SCLC	NCT06892548	AMC
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants with Relapsed Small Cell Lung Cancer (25-2325)	Metastatic or extensive-stage small cell lung cancer	NCT06179069	AMC, HRH
Mesothelioma and Thymic Malignancies			
No current trials available			



Cancer Prevention and Survivorship Anschutz Medical Campus (AMC)		
Physician	Email	Phone
Marie Wood, MD	Marie.Wood@cuanschutz.edu	-

Cancer Prevention and Survivorship			
Study	Patients	NCT#	Sites
IL-6 and IL-6R Genetic Polymorphisms in Immune-Related Adverse Events Caused by Cancer Immunotherapy (25-0049)	Metastatic solid tumor of any type; starting new regimen of anti-CTLA4, anti PD1, anti PD-L-1 or anti LAG-3 therapy alone or in combination with standard of care	n/a	AMC
NRG-CC015: Harnessing E-Mindfulness Approaches for Living After Breast Cancer---HEAL-ABC (25-2629)	Stage 0, 1, 2, or 3 non metastatic breast cancer who have completed all primary breast cancer treatments at least 6 months but no more than 5 years ago, Age 18-50	NCT06748222	AMC
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (23-1087)	Various cohorts for multiple cancer types, gender and race cohorts.	NCT05334069	AMC



Satellite Site Contacts		
	Physician Leads	Nurse Navigators
CCMC	Scott Kono, MD (Scott.Kono@CUAnschutz.edu)	Lanie Wolff (lanie.wolff@uchealth.org) 720-516-9254
HRH	Elaine Lam, MD (Elaine.Lam@CUAnschutz.edu)	Tera Stewart (Tera.Stewart@CUAnschutz.edu) and Kara Ickler (Kara.Ickler@CUAnschutz.edu)
LT	Corbin Eule, MD (Corbin.Eule@CUAnschutz.edu)	Crystal Stribling (CrystalD.Stribling@uchealth.org)

Common Eligibility Criteria for Clinical Trials	
Performance Status	ECOG 0-1 Karnofsky Performance Status $\geq$ 60
Age	Age $\geq$ 18 years (ask for sarcoma trials)
Measurable disease	Lesions that can be accurately measured in at least one dimension with a minimum size requirement: • For CT or MRI scans: ○ The lesion must be ≥ 10 mm in its longest diameter. ○ For lymph nodes, the short axis must be ≥ 15 mm to be considered measurable. • For physical exam or clinical measurement: ○ The lesion must be ≥ 10 mm in its longest dimension and should be measurable with a caliper or ruler. • For ultrasound: ○ Lesions can only be considered measurable if they are confirmed by CT or MRI measurements. Non-Measurable Lesions: • Lesions that do not meet the criteria above are classified as non-measurable. • Please note that bone lesions (unless there is soft tissue extension), pleural effusions, or ascites are not considered measurable disease.
Adequate organ and bone marrow function	Bone marrow: ANC $\geq$ 1.5, Hgb $\geq$ 9.0 (without recent transfusion), platelets $\geq$ 100 (without recent transfusion). Hepatic: AST and ALT $<$ 2 x ULN, bilirubin $<$ 2.0. Renal: CrCl $\geq$ 50 ml/min. Cardiovascular: No symptomatic congestive heart failure; no MI, CVA, or unstable angina in the past 6 months. Pulmonary: History of ILD requiring steroids (protocol dependent). Neurologic: If brain metastases are present, they must have been treated and not progressing.